Recruiting
Hormone-refractory prostate cancer+1
RecruitingStudy of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy
Registered drugNo placebo
Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy
Registered drugNo placebo
- Disease:Hormone-refractory prostate cancerProstate cancer metastatic
- Substances:AbirateroneDarolutamide+4
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Abiraterone



